AAAAAA

   
Results: 1-8 |
Results: 8
Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: A pilot prospective study
Authors: Fulghesu, AM Ciampelli, M Belosi, C Apa, R Guido, M Caruso, A Mancuso, S Lanzone, A
Citation: Am. Fulghesu et al., Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: A pilot prospective study, J ENDOC INV, 24(7), 2001, pp. 483-490
A new ultrasound criterion for the diagnosis of polycystic ovary syndrome:the ovarian stroma/total area ratio
Authors: Fulghesu, AM Ciampelli, M Belosi, C Apa, R Pavone, V Lanzone, A
Citation: Am. Fulghesu et al., A new ultrasound criterion for the diagnosis of polycystic ovary syndrome:the ovarian stroma/total area ratio, FERT STERIL, 76(2), 2001, pp. 326-331
Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism
Authors: De Leo, V Fulghesu, AM la Marca, A Morgante, G Pasqui, L Talluri, B Torricelli, M Caruso, A
Citation: V. De Leo et al., Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism, GYNECOL END, 14(6), 2000, pp. 411-416
Changes in luteinizing hormone and insulin secretion in polycystic ovariansyndrome
Authors: Fulghesu, AM Cucinelli, F Pavone, V Murgia, F Guido, M Caruso, A Mancuso, S Lanzone, A
Citation: Am. Fulghesu et al., Changes in luteinizing hormone and insulin secretion in polycystic ovariansyndrome, HUM REPR, 14(3), 1999, pp. 611-617
Impact of insulin and body mass index on metabolic and endocrine variablesin polycystic ovary syndrome
Authors: Ciampelli, M Fulghesu, AM Cucinelli, F Pavone, V Ronsisvalle, E Guido, M Caruso, A Lanzone, A
Citation: M. Ciampelli et al., Impact of insulin and body mass index on metabolic and endocrine variablesin polycystic ovary syndrome, METABOLISM, 48(2), 1999, pp. 167-172
Comment on "Prevalence and predictors of risk for type 2 diabetes mellitusand impaired glucose tolerance in polycystic ovary syndrome"
Authors: Ciampelli, M Fulghesu, AM Lanzone, A
Citation: M. Ciampelli et al., Comment on "Prevalence and predictors of risk for type 2 diabetes mellitusand impaired glucose tolerance in polycystic ovary syndrome", J CLIN END, 84(8), 1999, pp. 2974-2975
Influence of body mass on the hypothalamic-pituitary-adrenal-axis responseto naloxone in patients with polycystic ovary syndrome
Authors: Guido, M Ciampelli, M Fulghesu, AM Pavone, V Barini, A De Marinis, L Cento, R Caruso, A Lanzone, A
Citation: M. Guido et al., Influence of body mass on the hypothalamic-pituitary-adrenal-axis responseto naloxone in patients with polycystic ovary syndrome, FERT STERIL, 71(3), 1999, pp. 462-467
Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism
Authors: Villa, P Valle, D Mancini, A De Marinis, L Pavone, V Fulghesu, AM Mancuso, S Lanzone, A
Citation: P. Villa et al., Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism, FERT STERIL, 71(1), 1999, pp. 115-121
Risultati: 1-8 |